[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review]
- PMID: 18718102
[Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review]
Abstract
Allogeneic haematopoietic stem cell transplantation (allo-HCT) is the most effective curative therapy in myelodysplastic syndromes (MDS). Incidence of MDS increases with age, peaking in the seventh decade of last century. Despite improved consolidation chemotherapy regimens, the prognosis of MDS in patients beyond 60 years of age is dismal. The introduction of peripheral blood-derived stem cell grafts into allogeneic HSCT and the known anti-tumor effect of donor lymphocyte infusions paved the way for reduced-intensity conditioning (RIC) allogeneic hematopoietic stem-cell transplantation, which makes transplant possible in advanced age, significantly alleviates transplant-related organ toxicity and decreases non-relapse mortality. This article reviews the advanced development of reduced-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes and the future of reduced intensity conditioning hematopoietic stem cell transplants including feasibility of RIC allo-HSCT in treating patients with MDS, selection of MDS cases for RIC allo-HSCT, opportunity of RIC allo-HSCT, source of stem cells for RIC allo-HSCT, RIC regimen for allo-HSCT, evaluation of curative efficacy and prognosis, GVHD and graft versus MDS, and so on.
Similar articles
-
Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.Leukemia. 2007 Jul;21(7):1357-62. doi: 10.1038/sj.leu.2404741. Epub 2007 May 17. Leukemia. 2007. PMID: 17508002 Review.
-
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012. Biol Blood Marrow Transplant. 2009. PMID: 19135940
-
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.Cancer. 2017 Jul 15;123(14):2661-2670. doi: 10.1002/cncr.30632. Epub 2017 Mar 21. Cancer. 2017. PMID: 28324640
-
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2. Biol Blood Marrow Transplant. 2018. PMID: 29305194 Free PMC article.
-
Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.Transfus Apher Sci. 2011 Apr;44(2):205-10. doi: 10.1016/j.transci.2011.01.019. Epub 2011 Feb 22. Transfus Apher Sci. 2011. PMID: 21345734 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous